Healthcare DIVE October 2, 2024
It’s the first time this type of model has been used to bring a Humira biosimilar to market, according to the insurer.
Dive Brief:
- A major California health plan has struck a novel deal directly with a drug manufacturer for a cheaper version of Humira, cutting out pharmacy benefit managers — controversial middlemen in the drug supply chain that typically control access to medication — entirely.
- As a result of the deal, Blue Shield of California will purchase a Humira biosimilar for $525 per monthly dose, significantly below the drug’s net price of $2,100.
- The biosimilar will be available for most of BSCA’s commercial members at $0 co-pay starting Jan. 1, 2025, according to the insurer, which announced the...
Today's Sponsors
Today's Sponsor